Visual fields . | . | . | Tumour volume . | Drug . | Reference . | ||
---|---|---|---|---|---|---|---|
Improved . | Stable . | Worsened . | Growth . | Stable . | Shrinkage . | . | . |
0/11 | 2/11 | 9/11 | Bromocriptine | 85 | |||
0/12 | 6/12 | 6/12 | Bromocriptine | 86 | |||
0/15 | 15/15 | 0/15 | Bromocriptine/mesulergine/pergolide | 87 | |||
1/5 | 4/5 | 0/5 | 0/5 | 1/5 | 4/5 | Bromocriptine | 88 |
1/20 | 15/20 | 4/20 | 0/20 | 19/20 | 1/20 | Bromocriptine | 89 |
0/7 | 7/7 | 0/7 | Bromocriptine | 90 | |||
3/3 | 0/3 | 0/3 | Bromocriptine | 91 | |||
0/8 | 8/8 | 0/8 | Bromocriptine | 92 | |||
0/4 | 2/4 | 2/4 | Bromocriptine | 93 | |||
1/25 | 23/25 | 1/25 | 1/25 | 20/25 | 4/25 | Bromocriptine | 95 |
2/5 | 3/5 | 0/5 | 0/5 | 4/5 | 1/5 | Quinagolide | 96 |
0/6 | 4/6 | 2/6 | Quinagolide | 97 | |||
0/10 | 6/10 | 4/10 | 6/10 | 4/10 | 0/10 | Quinagolide | 99 |
3/10 | 7/10 | 0/10 | 0/10 | 8/10 | 2/10 | Quinagolide/cabergoline | 98 |
2/13 | 11/13 | 0/13 | 0/13 | 6/13 | 7/13 | Cabergoline | 100 |
4/9 | 5/9 | 0/9 | 3/9 | 1/9 | 5/9 | Cabergoline | 82 |
7/33 | 15/33 | 11/33 | Bromocriptine | 101 | |||
17/100 | 74/100 | 9/100 | 17/193 | 122/193 | 54/193 | Overall | |
17% | 74% | 9% | 9% | 63% | 28% |
Visual fields . | . | . | Tumour volume . | Drug . | Reference . | ||
---|---|---|---|---|---|---|---|
Improved . | Stable . | Worsened . | Growth . | Stable . | Shrinkage . | . | . |
0/11 | 2/11 | 9/11 | Bromocriptine | 85 | |||
0/12 | 6/12 | 6/12 | Bromocriptine | 86 | |||
0/15 | 15/15 | 0/15 | Bromocriptine/mesulergine/pergolide | 87 | |||
1/5 | 4/5 | 0/5 | 0/5 | 1/5 | 4/5 | Bromocriptine | 88 |
1/20 | 15/20 | 4/20 | 0/20 | 19/20 | 1/20 | Bromocriptine | 89 |
0/7 | 7/7 | 0/7 | Bromocriptine | 90 | |||
3/3 | 0/3 | 0/3 | Bromocriptine | 91 | |||
0/8 | 8/8 | 0/8 | Bromocriptine | 92 | |||
0/4 | 2/4 | 2/4 | Bromocriptine | 93 | |||
1/25 | 23/25 | 1/25 | 1/25 | 20/25 | 4/25 | Bromocriptine | 95 |
2/5 | 3/5 | 0/5 | 0/5 | 4/5 | 1/5 | Quinagolide | 96 |
0/6 | 4/6 | 2/6 | Quinagolide | 97 | |||
0/10 | 6/10 | 4/10 | 6/10 | 4/10 | 0/10 | Quinagolide | 99 |
3/10 | 7/10 | 0/10 | 0/10 | 8/10 | 2/10 | Quinagolide/cabergoline | 98 |
2/13 | 11/13 | 0/13 | 0/13 | 6/13 | 7/13 | Cabergoline | 100 |
4/9 | 5/9 | 0/9 | 3/9 | 1/9 | 5/9 | Cabergoline | 82 |
7/33 | 15/33 | 11/33 | Bromocriptine | 101 | |||
17/100 | 74/100 | 9/100 | 17/193 | 122/193 | 54/193 | Overall | |
17% | 74% | 9% | 9% | 63% | 28% |
Modified from Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer, 2008; 15: 905–15. (1).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.